Yanchen Liu, Jing Zhu, Hao Zhang, Yiwei Jiang, Huning Wang, Jin Yu, Dongxing Da, Qiwen Chen, Hongru Su, Zhengang Wu, Hongyan Shi, Jiangtao You, Xiaoli Zeng, Ying Zhang
Dental caries status and related factors among 5-year-old children in Shanghai
BMC oral health
guidelines cholesterollowering treatment generally include extensive review epidemiological clinical trial evidence however next logical step translation evidence clinical advice occurs entirely reasoning form consensus prejudices established beliefs societies interests cardiovascular disease convened interpret evidence prominent methods subject review however developed clinical trial evidence translated objectively best practice guidelines differ recommended goals cholesterollowering treatment prevention atherosclerotic cardiovascular disease ascvd proposed goals ldlcholesterol 26 mmoll 100 mgdl less lower risk ldlcholesterol 18 mmoll 70 mgdl less higher risk nonhdlcholesterol decrease least 40 ldlcholesterol 18 mmoll 70 mgdl less decreased least 50 whichever lower evidence clinical trials statins ezetimibe proprotein convertase subtilisinkexin type 9inhibitors expressed simple mathematical terms compare efficacy ascvd incidence clinical guidance use cholesterollowering medication target ldlcholesterol 26 mmoll 100 mgdl ineffective lacks credibility cholesterollowering medication effective highrisk people raised ldlcholesterol best overall therapeutic target ldlcholesterol 18 mmoll 70 mgdl less decreased least 50 whichever lower use nonhdlcholesterol therapeutic goal less efficacious aiming ldlcholesterol 14 mmoll 55 mgdl less opposed 18 mmoll produces small additional benefit evidence apolipoprotein b targets hypertriglyceridaemia high ascvd risk prominent future guidelines ldlcholesterol goal 26 mmoll less abandoned percentage decreases ldlcholesterol nonhdlcholesterol concentration better people initial concentrations less 36 mmoll ldlcholesterol target 18 mmoll effective initial ldlcholesterol 36 mmoll primary secondary prevention